Meet our Team
The Leadership Team
David Dingott
CEO and Founder, Sword Bio
Dave is Fortune 10 trained, with 30 years of business leadership. He founded Sword Bio and is positioned with a proven, successful team, to drive it to its next level of growth. He was Co-Founder of Corente
’which was sold to Oracle, and he served as a Board Member of Cearna, until its successful sale to Abbvie.
Jim McNally, Ph.D
Chief Scientific Officer
Dr. McNally has an extensive background in bioanalytical assay development and biotherapeutic program leadership spanning more than 25 years working in the pharmaceutical and biotechnology industry. Prior to joining Sword Bio,
Dr. McNally served for 5 years as Chief Scientific Officer for BioAgilytix. Previously, Dr. McNally was Executive Director at CRISPR Therapeutics, where he lead a team of scientists to develop a portfolio of assays to support development of gene-based therapeutic candidates throughout their lifecycle. He has also held roles at Genzyme, Pfizer, EMD Serono, and Shire which have given him broad experience in the development of large molecule, gene therapy, and cell therapy biotherapeutics. Dr. McNally is a recognized thought leader in the development and application of bioanalytical methods used in regulatory submissions and is specifically skilled in progression of biotherapeutics from research through clinical development. He has a special interest in the immunogenicity of biotherapeutics and has led industry-wide working group to address this issue. A key part of his role at Sword Bio is leading the scientific strategy for Sword and advising on emerging scientific developments while providing scientific and regulatory guidance. Dr. McNally obtained his B.S. in Biology from Mississippi State University, his Ph.D. Viral Immunology from Louisiana State University School of Medicine, and his Post-Doc in Viral Immunology from University of Massachusetts Medical School.
Amanda Rom
GM Of Chicago Laboratory.
Amanda is the GM, Operations for the Chicago Laboratory. She brings expertise in Large Molecule Bioanalysis, Virology, and Molecular Biology from her over 30 years of experience working for Contract
Research Organizations. Amanda has served as the Principal Investigator for both non-clinical and clinical regulated studies. Most recently, she was responsible for the start-up and management of a Molecular Biology unit at that Charles River Laboratory Skokie site. Utilizing her scientific and regulatory knowledge as well as and people leader skills to have the group ready for regulated studies in less than a year. Amanda is dedicated to providing quality services to clients by fostering a high-performing team and driving operational excellence.
David Osband
EVP, Sales and Marketing
David Osband is EVP, Sales and Marketing at Sword Bio. Prior to Sword Bio, David was an owner of Cambridge Biomedical, a bioanalytical CRO with expertise in PK, Biomarker and Immunogenicity development,
validation and sample testing for preclinical through Phase IV trials. For the last 13 years David has been involved in successfully growing and operating diagnostic and contract research laboratory businesses. David’s focus is always on finding a way to offer a superior level of quality, science and service to the market than what currently exists. David believes the speed of Sword’s project start-up and completion for preclinical through Phase IV trials, white-glove service complimented by the team’s expertise in the areas of PK, Biomarker and immunogenicity, he can offer another unique product to his partners. Always understanding that at the end of the day the employees, clients and patients are all connected.